Exploratory subgroup analysis in clinical trials by model selection
Abstract
The interest in individualized medicines and upcoming or renewed regulatory requests to assess treatment effects in subgroups of confirmatory trials requires statistical methods that account for selection uncertainty and selection bias after having performed the search for meaningful subgroups. The challenge is to judge the strength of the apparent findings after mining the same data to discover them. In this paper, we describe a resampling approach that allows to replicate the subgroup finding process many times. The replicates are used to adjust the effect estimates for selection bias and to provide variance estimators that account for selection uncertainty. A simulation study provides some evidence of the performance of the method and an example from oncology illustrates its use.
Citing Literature
Number of times cited according to CrossRef: 13
- Alex Dmitrienko, Ilya Lipkovich, Aaron Dane, Christoph Muysers, Data-Driven and Confirmatory Subgroup Analysis in Clinical Trials, Design and Analysis of Subgroups with Biopharmaceutical Applications, 10.1007/978-3-030-40105-4_3, (33-91), (2020).
- Nicolás M. Ballarini, Yi‐Da Chiu, Franz König, Martin Posch, Thomas Jaki, A critical review of graphics for subgroup analyses in clinical trials, Pharmaceutical Statistics, 10.1002/pst.2012, 19, 5, (541-560), (2020).
- Duy Ngo, Richard Baumgartner, Shahrul Mt-Isa, Dai Feng, Jie Chen, Patrick Schnell, Bayesian credible subgroup identification for treatment effectiveness in time-to-event data, PLOS ONE, 10.1371/journal.pone.0229336, 15, 2, (e0229336), (2020).
- Xinzhou Guo, Xuming He, Inference on Selected Subgroups in Clinical Trials, Journal of the American Statistical Association, 10.1080/01621459.2020.1740096, (1-18), (2020).
- TianHong Zhang, JunJie Wang, LiHua Xu, YanYan Wei, XiaoChen Tang, YeGang Hu, HuiRu Cui, YingYing Tang, Li Hui, ChunBo Li, JiJun Wang, Subtypes of Clinical High Risk for Psychosis that Predict Antipsychotic Effectiveness in Long-Term Remission, Pharmacopsychiatry, 10.1055/a-1252-2942, (2020).
- Marius Thomas, Björn Bornkamp, Martin Posch, Franz König, A multiple comparison procedure for dose‐finding trials with subpopulations, Biometrical Journal, 10.1002/bimj.201800111, 62, 1, (53-68), (2019).
- R. O. Ganzha, Modeling of the Type of Surgical Intervention for Breast Cancer According to Mammography Examination: Analysis of Factors, Statistics of Ukraine, 10.31767/su.3(86)2019.03.09, 86, 3, (82-89), (2019).
- Aaron Dane, Amy Spencer, Gerd Rosenkranz, Ilya Lipkovich, Tom Parke, Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis, Pharmaceutical Statistics, 10.1002/pst.1919, 18, 2, (126-139), (2018).
- Nicolás M. Ballarini, Gerd K. Rosenkranz, Thomas Jaki, Franz König, Martin Posch, Subgroup identification in clinical trials via the predicted individual treatment effect, PLOS ONE, 10.1371/journal.pone.0205971, 13, 10, (e0205971), (2018).
- Julien Tanniou, Ingeborg Tweel, Steven Teerenstra, Kit C.B. Roes, Estimates of subgroup treatment effects in overall nonsignificant trials: To what extent should we believe in them?, Pharmaceutical Statistics, 10.1002/pst.1810, 16, 4, (280-295), (2017).
- Ilya Lipkovich, Alex Dmitrienko, Christoph Muysers, Bohdana Ratitch, Multiplicity issues in exploratory subgroup analysis, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1397009, (1-19), (2017).
- Björn Bornkamp, David Ohlssen, Baldur P. Magnusson, Heinz Schmidli, Model averaging for treatment effect estimation in subgroups, Pharmaceutical Statistics, 10.1002/pst.1796, 16, 2, (133-142), (2016).
- Marius Thomas, Björn Bornkamp, Comparing Approaches to Treatment Effect Estimation for Subgroups in Clinical Trials, Statistics in Biopharmaceutical Research, 10.1080/19466315.2016.1251490, 9, 2, (160-171), (2016).




